GrobnerT. Gadolinium: a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis. Nephrol Dial Transplant2006;21:1104–8
2.
MarckmannP, SkovL, RossenK, Nephrogenic systemic fibrosis: suspected causative role of gadodiamide used for contrast-enhanced magnetic resonance imaging. J Am Soc Nephrol2006:17:2359–62
3.
EvansCH, DrouvenBJ. The promotion of collagen polymerization by lanthanide and calcium ions. Biochem J1983;213:751–8
4.
EvansCH. Biochemistry of the lanthanides. New York, NY: Plenum Press, 1990
5.
SMRM workshop on contrast enhanced magnetic resonance. Discussion. Magn Reson Med1991;22:229–32
6.
MüllerN, GünzelP, SchöbelC. Ionic and non-ionic gadolinium-containing magnetic resonance contrast media. Comparison of effects and their reversibility in repeated dose toxicity studies in rats. Advances in MRI Contrast1992;1 (Suppl. 1):15–28
7.
MatonF, van der ElstL, MullerRN. Influence of human proteins on the relaxivity of Gd(III) complexes. See http://www.b.dk/upload/webred/bmsandbox/uploads/2012/03/bb81a28663015b7a1d828ee723de7a26.pdf
8.
FrenzelT, LengsfeldP, SchirmerH, Stability of gadolinium based magnetic resonance imaging contrast agents in human serum at 37°C. Invest Radiol2008;43:817–28
9.
BennettCL, StarkoKM, ThomsenHS, Linking drugs to obscure illness: lessons from pure red cell aplasia, nephrogenic systemic fibrosis, and Reye's syndrome. A report from the Southern Network on adverse reactions (SONAR). J Gen Intern Med2012 Jun 13; doi: 10.1007/s11606-012-2098-1
GiradiM, KayJ, ElstonDM, Nephrogenic systemic fibrosis: clinicopathological definition and workup recommendations. J Am Acad Dermatol2011;65:1095–106
12.
CaravanP, EllisonJJ, McMurryTJ, Gadolinium (III) chelates and MRI agents: Structure, dynamics and applications. Chem Rev1999;99:2293–352
13.
BennettCL, QureshiZP, SatorOA, Gadolinium induced nephrogenic systemic fibrosis, the rise and fall of an iatrogenic disease. Clin Kidney J2012;5:82–88
14.
PirovanoG, MunleyJ, SchultzC, Nephrogenic systemic fibrosis: a review of published cases and results from three prospective observational studies. ECR2012;3 (Suppl. 1):S293
15.
AmetS, ChoukrounG, Launay-VacherV, Prevalence of nephrogenic systemtic fibrosis in dialysis patients: the Pro-FINEST study. ECR2012;3 (Suppl. 1):S293
16.
ThomsenHS. ESUR guideline: gadolinium-based contrast media and nephrogenic systemic fibrosis. Eur Radiol2007;17:2692–6
17.
WhiteGW, GibbyWA, TweedleMF. Comparison of Gd (DTPA-BMA) (Omniscan) versus Gd(HP-DO3A) (ProHance) relative to gadolinium retention in human bone tissue by inductively coupled plasma mass spectroscopy.Invest Radiol2006;41:272–8
